| Patient | Josephine Baker |
|---|---|
| Date of birth | 1963-06-03 |
| Identifiers | MRN HR-ML049-SYN; SSN (made up) 000-49-3172 |
| Document date | 2026-04-28 |
| Author | Colette Ashby-Nwosu, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review: echocardiogram, cardiology consultation and breathlessness. [S]
Ms. Baker returns two weeks after intake and is seen the same day by Dr. Mbeki-Fontaine of cardiology after her echocardiogram this morning. She is still breathless, but she describes it more exactly now: a sudden need to take a deep breath, often while sitting still or talking, as if she cannot get enough air, which began two or three days after she left the hospital. It does not build with effort the way it did on the day of the heart attack, and she has had no chest pressure, palpitations, ankle swelling, cough or waking at night breathless. She has taken every dose of aspirin, ticagrelor, atorvastatin, metoprolol and lisinopril, and has not needed nitroglycerin. Her home blood pressure averages 136/82. She has been to two cardiac rehabilitation sessions; on the treadmill she was not limited by breath. She is sleeping a little better. [S]
| Element | Detail |
|---|---|
| Breathlessness | Air hunger at rest and while talking, from two or three days after discharge; not exertional; no chest pain |
| Echocardiogram | Ejection fraction 52%; inferior hypokinesis; normal filling pressures |
| Home blood pressure | Average 136/82 mmHg |
| Rehabilitation | Two sessions completed without limiting breathlessness |
| Lipoprotein(a) | 172 nmol/L |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Episodes of air hunger at rest; no cough, wheeze or night breathlessness |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea or ankle swelling |
| Hematologic/lymphatic | Negative | No bleeding or unusual bruising |
| Psychiatric | Positive | Still worried about money and her children; sleeping a little better |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-24 | active | S |
| Ticagrelor 90 mg oral tablet, one tablet twice daily | One tablet twice daily | Oral route | 2026-03-24 to 2026-04-28 | completed | S |
| Clopidogrel 75 mg oral tablet: a 600 mg loading dose (eight tablets) 24 hours after the last ticagrelor, then one tablet daily | One tablet daily after a 600 mg loading dose | Oral route | 2026-04-28 | active | S |
| Atorvastatin 80 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-24 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-24 | active | S |
| Lisinopril 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-24 to 2026-04-28 | completed | S |
| Lisinopril 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-04-28 | active | S |
| Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if the pain is not better 5 minutes after the first tablet | One tablet under the tongue every 5 minutes as needed for chest pain, up to 3 doses | Sublingual route | 2026-03-24 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-28 | Body height | 168 | cm | S |
| 2026-04-28 | Body weight | 59.6 | kg | S |
| 2026-04-28 | Body mass index (BMI) [Ratio] | 21.1 | kg/m2 | S |
| 2026-04-28 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-04-28 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-04-28 | Heart rate | 62 | /min | S |
| 2026-04-28 | Respiratory rate | 16 | /min | S |
| 2026-04-28 | Body temperature | 36.7 | Cel | S |
| 2026-04-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-28 | Lipoprotein a [Moles/volume] in Serum or Plasma | 172 | nmol/L | 125 nmol/L or higher is a risk-enhancing level | High | S |
| 2026-04-28 | Left ventricular Ejection fraction | 52 | % | 50-70% | Normal | S |
Vital signs recorded on 2026-04-28; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; talking in full sentences; blood pressure 136/82, pulse 62; oxygen saturation 98% on room air; weight 59.6 kg |
| Neck | Jugular venous pressure not raised |
| Cardiovascular | Regular rhythm; normal heart sounds; no murmur or gallop; right radial access site healed |
| Respiratory | Clear; no crackles or wheeze |
| Extremities | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion and tiredness since discharge three weeks after the heart attack, without chest pain at rest; cause to be determined (heart function, ischemia, anemia, medicine effect or deconditioning) | resolved | confirmed | R06.09 | S — Synthetic presenting problem, resolved at the second visit when the echocardiogram and cardiology attributed it to ticagrelor. |
| Coronary artery disease after a non-ST-elevation myocardial infarction three weeks before intake, treated with one drug-eluting stent to the right coronary artery; synthetic modern episode linked to the documented heart attack of March 1969 | active | confirmed | I25.10 | S — Synthetic modern diagnosis; the 1969 heart attack remains D in the history. |
| High blood pressure, found during the hospital stay for the heart attack | active | confirmed | I10 | S — Synthetic modern diagnosis; no claim about her real blood pressure. |
| Absence of the uterus after an emergency hysterectomy at about 35, during a long, grave illness after the loss of a pregnancy; whether the ovaries were removed is not known; counted as a possible early menopause when weighing her cardiovascular risk | active | provisional | Z90.710 | S — Synthetic modern status linked to the retrospective account of a hysterectomy in 1941 or 1942; the operation itself rests on one secondary source. |
| Breathlessness from ticagrelor: a common, harmless side effect, resolved after the change to clopidogrel | active | confirmed | T45.525A | S — Synthetic diagnosis at the second visit; resolved at the third visit after the switch. |
| Raised lipoprotein(a), 172 nmol/L, an inherited risk-enhancing factor | active | confirmed | E78.41 | S — Synthetic result measured once at the second visit. |
| Financial strain: heavy debts after the loss of her home and estate, with income only from performing, which she has stopped while she recovers | active | confirmed | Z59.86 | S — Synthetic social need anchored to her documented debts and the loss of Les Milandes. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (seated, average of two readings; home readings) | Every visit | Completed today | 136/82 mmHg; home average 136/82; above target |
| Examination | Weight, BMI and physical activity | Every visit | Completed today | 59.6 kg, BMI 21.1; two rehabilitation sessions |
| Medication safety | Adherence: aspirin and P2Y12 inhibitor through the dual antiplatelet window, high-intensity statin, beta-blocker, ACE inhibitor | Every visit | Completed today | No missed doses; ticagrelor stopped for breathlessness and replaced by clopidogrel with a loading dose |
| Medication safety | Bleeding on dual antiplatelet therapy (symptoms, hemoglobin when indicated) | Every visit | Completed today | No bleeding; hemoglobin 12.2 g/dL at intake |
| Imaging | Echocardiogram for left ventricular function | After the infarction if not done or if function was reduced; then only with clinical change | Completed today | Ejection fraction 52%, inferior hypokinesis, normal filling pressures, no thrombus |
| Laboratory | Lipoprotein(a) | Once | Completed today | 172 nmol/L, a risk-enhancing level |
| Laboratory | Lipid panel | Four to eight weeks after a statin start or change, then every three to twelve months | Ordered | LDL 84 mg/dL at intake, only three weeks after atorvastatin 80 mg was started; panel ordered with the potassium check in one to two weeks |
| Laboratory | Metabolic panel (potassium, creatinine, eGFR) on an ACE inhibitor | One to two weeks after a start or dose change, then every six to twelve months | Ordered | Potassium 4.4, creatinine 0.82 mg/dL at intake; lisinopril raised today, panel due in one to two weeks |
| Laboratory | Hemoglobin A1c (no diabetes) | Yearly screening | Up to date | 5.6% at intake |
| Examination | ECG and troponin | Only with new or changing symptoms | Not indicated | No angina or change in symptoms suggesting ischemia; ECG at intake showed no acute change |
| Survey | Angina status (Seattle Angina Questionnaire-7) | At intake and every few months in the first year | Up to date | 70 at intake; next at the next visit |
| Survey | Depression screen (PHQ-2, then PHQ-9) | After the infarction and periodically | Up to date | PHQ-9 7 at intake with item 9 scored 0; repeat at about twelve weeks |
| Examination | Tobacco use | Every visit | Completed today | Never smoker |
| Referral | Cardiac rehabilitation | Within weeks of the infarction; 36 sessions | Completed today | Enrolled; two sessions completed |
| Self-management | Self-management: chest-pain action plan, nitroglycerin, women's warning symptoms | Every visit | Completed today | Action plan reviewed; nitroglycerin not needed |
| Medication safety | Medicine and visit costs | Every visit | Completed today | Clopidogrel is a low-cost generic; social worker next week |
| Referral | Cardiology consultation | After the infarction | Completed today | Seen by Dr. Mbeki-Fontaine today |
Goal progress:
Guideline basis: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025); Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association (2016); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and acute myocardial infarction monographs (2026)
Follow-up: Metabolic panel in one to two weeks. Review in four weeks. Call for breathlessness that worsens, bleeding, or lightheadedness; call 911 for chest pain not relieved five minutes after one nitroglycerin. Next scheduled visit 2026-05-26: four-week review after the change to clopidogrel: breathlessness, blood pressure, potassium and kidney function, and cardiac rehabilitation. [S]